New Committee on Rheumatologic Care (CORC) Chair Chris Phillips, MD, talks about his past work with the ACR, his experience as a private practice rheumatologist and his plans to lead CORC in addressing practitioner pain points and supporting the business side of rheumatology practice.
Search results for: infliximab
ACR Advocates with Payers Against Insufficient Reimbursement for Biosimilars
The ACR is engaging with payers regarding formulary requirements that would leave practices underwater when treating patients with rheumatic diseases.
The Eyes Have It
SAN DIEGO—Many rheumatologists see patients referred for uveitis, and Laura Kopplin, MD, PhD, assistant professor of ophthalmology and visual sciences, University of Wisconsin, Madison, discussed inflammatory disease of the eye at ACR Convergence 2023.
Marching to the Biosimilar Beat: Questions on Rollout Remain
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
Psoriatic Arthritis Drugs at a Glance, 2023
Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…
Long COVID: Experts Weigh in on Increasingly Common Syndrome
A minority of patients experience lingering symptoms after infection with SARS-CoV-2, similar to some other previously known post-infection syndromes. Although we are just beginning to understand the different presentations, pathophysiology, risk factors, prognosis and treatment of long COVID, rheumatologists can play a leadership role in managing patients with the illness and contributing to this important research…
Key Facts on Billing Drug Wastage
The ACR has compiled guidelines and tips on how to use the JW modifier and correctly bill Medicare for discarded drugs and biologicals. This modifier can be applied only to unused amounts from a single-dose vial or package.
Highlights from the ACR Review Course 2022
PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 38
- Next Page »